Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-γc-/- mouse

Journal of Virology

Volumn 83, Issue 16, 2009, Pages 8254-8258

  Choudhary, Shailesh K ^a   Rezk, Naser L ^a   Ince, William L ^a   Cheema, Manzoor ^a   Zhang, Liguo ^b   Su, Lishan ^a,b   Swanstrom, Ronald ^a   Kashuba, Angela D M ^a   Margolis, David M ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; INTEGRASE INHIBITOR; L 870812; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; GENE REPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPH NODE; LYMPHOCYTE DEPLETION; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; SINGLE DRUG DOSE; SPLEEN; THYMUS; VIREMIA; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INTEGRASE INHIBITORS; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE INHIBITORS; VIREMIA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 67749106469     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00580-09     Document Type: Article

References (23)

1. Ambrose, Z., V. Boltz, S. Palmer, J. M. Coffin, S. H. Hughes, and V. N. KewalRamani. 2004. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78:13553-13561.
2. Ambrose, Z., S. Palmer, V. F. Boltz, M. Kearney, K. Larsen, P. Polacino, L. Flanary, K. Oswald, M. Piatak, Jr., J. Smedley, W. Shao, N. Bischofberger, F. Maldarelli, J. T. Kimata, J. W. Mellors, S. L. Hu, J. M. Coffin, J. D. Lifson, and V. N. KewalRamani. 2007. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J. Virol. 81:12145-12155.
3. -/- mice. Proc. Natl. Acad. Sci. USA 103:15951-15956.
4. -/- (RAG-hu) mice. Virology 373:342-351.
5. -/- (RAG-hu) mouse model. Retrovirology 3:76.
6. Blum, M. R., G. E. Chittick, J. A. Begley, and J. Zong. 2007. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate adiministered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47:751-759.
7. Denton, P. W., J. D. Estes, Z. Sun, F. A. Othieno, B. L. Wei, A. K. Wege, D. A. Powell, D. Payne, A. T. Haase, and J. V. Garcia. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5:e16.
8. Engelman, A., and R. Craigie. 1992. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66:6361-6369.
9. Gerton, J. L., S. Ohgi, M. Olsen, J. DeRisi, and P. O. Brown. 1998. Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. J. Virol. 72:5046-5055.
10. Hammer, S. M., J. J. Eron, Jr., P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. Montaner, D. D. Richman, P. G. Yeni, and P. A. Volberding. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
11. Miller, M., R. Danovich, S. Fransen, S. Gupta, W. Huang, Y. Ke, B. Nguyen, N. Parkin, C. Petropoulos, H. Teppler, M. Witmer, J. Zhao, and D. J. Hazuda. 2008. Analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from the Benchmrk 1 and 2, abstr. H-898. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
12. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
13. Hazuda, D. J., S. D. Young, J. P. Guare, N. J. Anthony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt, S. L. Motzel, H. J. Klein, G. Dornadula, R. M. Danovich, M. V. Witmer, K. A. Wilson, L. Tussey, W. A. Schleif, L. S. Gabryelski, L. Jin, M. D. Miller, D. R. Casimiro, E. A. Emini, and J. W. Shiver. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532.
14. + cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus. J. Virol. 82:12145-12153.
15. Malet, I., O. Delelis, M.-A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J.-F. Mouscadet, C. Katlama, V. Calvez, and A.-G. Marcelin. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
16. Margot, N. A., E. Isaacson, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227-1235.
17. Markowitz, M., B. Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H. Wan, M. D. Miller, L. A. Wenning, and H. Teppler. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
18. North, T. W., K. K. Van Rompay, J. Higgins, T. B. Matthews, D. A. Wadford, N. C. Pedersen, and R. F. Schinazi. 2005. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J. Virol. 79:7349-7354.
19. Rezk, N. L., R. D. Crutchley, and A. D. Kashuba. 2005. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 822:201-208.
20. Stoddart, C. A., C. A. Bales, J. C. Bare, G. Chkhenkeli, S. A. Galkina, A. N. Kinkade, M. E. Moreno, J. M. Rivera, R. E. Ronquillo, B. Sloan, and P. L. Black. 2007. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS ONE 2:e655.
21. + T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204:705-714.
22. Traggiai, E., L. Chicha, L. Mazzucchelli, L. Bronz, J. C. Piffaretti, A. Lanzavecchia, and M. G. Manz. 2004. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104-107.
23. Zhang, L., G. I. Kovalev, and L. Su. 2007. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109:2978-2981.